IMW 2015


The Roman Colosseum and Arch of Constantine

The 15th International Myeloma Workshop took place September 23-26, 2015, in Rome, Italy.


Combo demonstrates potential in MM

HT Staff Read Article
Published: 09/29/15

Micrograph showing MM

Early results of a pilot study indicate that a 3-agent combination regimen can produce responses in patients with relapsed or refractory multiple myeloma (MM). The treatment consists of carfilzomib, dexamethasone, and pelareorep (Reolysin), a proprietary isolate of human reovirus (Type 3 Dearing strain). All 8 evaluable patients treated with this regimen experienced an objective response, although 1 patient later progressed.  [Read Article]

mAb produces ‘encouraging’ results in MM

HT Staff Read Article
Published: 09/28/15

Micrograph showing
multiple myeloma

Combination therapy incorporating a novel monoclonal antibody (mAb) can provide “encouraging, long-lasting tumor control” in heavily pretreated patients with relapsed/refractory multiple myeloma (MM), according to investigators. The mAb, MOR202, was also considered to be well-tolerated in this ongoing phase 1/2a study. Early results from this study were presented at the 15th International Myeloma Workshop. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}